Pandolfo, Alyssa M. http://orcid.org/0000-0003-0455-496X
Horne, Robert
Jani, Yogini
Reader, Tom W.
Bidad, Natalie
Brealey, David
Enne, Virve I.
Livermore, David M.
Gant, Vanya
Brett, Stephen J.
Barber, Julie
Shallcross, Laura
Cuesta, Jeronimo
Peters, Mark
Klein, Nigel
Moondi, Parvez
O’Grady, Justin
High, Juliet
Russell, Charlotte
Swart, Ann Marie
Turner, David
Singh, Suveer
,
Funding for this research was provided by:
Programme Grants for Applied Research (RP-PG-0514- 493 20018)
Article History
Received: 26 February 2021
Accepted: 9 June 2021
First Online: 29 June 2021
Declarations
:
: This research received ethical approval from the Camden and Kings Cross Research Ethics Committee (16/LO/1618). All participants provided informed written consent.
: Not applicable.
: DB reports personal fees (lecture fees) from bioMerieux, outside the submitted work. VIE reports personal fees and non-financial support from bioMerieux, personal fees from Curetis GmbH, and non-financial support from Oxford Nanopore Technologies, outside the submitted work. DML reports personal fees from Accelerate, Allecra, Antabio, Astellas, Beckman Coulter, bioMerieux, Cepheid, Centauri, Entasis, Johnson & Johnson, Meiji, Melinta, Menarini, Mutabilis, Nordic, ParaPharm, QPEX, Roche, Shionogi, Tetraphase, Wockhardt, 471 Zambon, Cardiome, and Eumedica. He also reports grants and personal fees from VenatoRx; personal fees and other (shareholder) from GlaxoSmithKline; personal fees and other (stock options) from T.A.Z.; grants, personal fees, and other (shareholder) from Merck/MSD and Pfizer; other (shareholder) from Perkin Elmer and Dechra. He also has nominated holdings in Avacta, Byotrol, Destiny, Diaceutics, Evgen, Faron, Fusion Antibodies, Genedrive, Hardide, Renalytics, Scancell and Synairgen (all of which have research/products pertinent to medical and diagnostic innovation) through Enterprise Investment Schemes, but has no authority to trade these shares directly. All are outside the submitted work. VG reports receiving speaking honoraria from bioMerieux and support for conference attendances from Merck/MSD and Gilead, outside the submitted work. Other authors have no potential conflicts of interest.